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Summary
The study describes cardiovascular changes in patients
with acromegaly before and one year after treatment.
Background
Acromegaly causes a distinct cardiomyopathy, which
remains poorly understood, because cardiac changes
typically appear before the development of hypertension
or diabetes.
The aim of the study was to describe cardiovascular
changes in patients with acromegaly before and one
year after treatment.
Methods
Thirteen patients with acromegaly and age- and sex-
matched controls (n=13) underwent CMR. Patients
underwent scans before disease treatment and at twelve
months after treatment. Cardiac parameters were calcu-
lated and indexed to body surface area (BSA). The com-
parison between groups was done using Mann-U-
Whitney test and within the group using Wilcoxon test.
Results
In patients with acromegaly left ventricular (LV) mass
index (LVMi) was increased (65.7 vs. 45.8 g/m2,
p=0.0021) and was observed in both females (58.8 v.
40.9 g/m2, p=0.0028) and males (71.1 vs. 56.7 g/m2,
p=0.0286) compared to matched controls. The LVMi
did not correlate with the serum insulin growth factor
(IGF) activity (r=0.099, p=0.745) or age (r=-0.08,
p=0.175).
Patients with acromegaly had significantly higher car-
diac index (CI; 3.7 vs. 3.0 l/min/m2, p=0.021) However,
there were no differences between end diastolic volume
index (EDVi; 86.9 vs. 75.4 ml/m2, p=0.0649), end systo-
lic volume index (ESVi; 35.1 vs. 29.3 ml/m2, p=0.1662)
and ejection fraction (EF; 60 vs. 59 %, p=0.327) in acro-
megaly group and controls.
There were no differences between right ventricular
(RV) RVEDVi (81.3 vs. 72.5 ml/m2, p=0.2382), RVESVi
(32.7 vs. 29.1, p=0.6816) and RVEF (61 vs. 59 %,
p=0.4407) in the acromegaly group and controls.
At one year, patients with acromegaly demonstrated a
significant fall in IGF with treatment (with somatostatin
analogues or transphenoidal surgery) from baseline
median IGF-I SDS +10.58 (range 1.19 to 6.52) to +0.40
(range -1.93 to 3.02) at one year (p=0.0042). CMR para-
meters of the LV did not change after 1 year of therapy:
LVMi 65.7 vs. 61.0 g/m2, p=0.0547; EDVi 89.5 vs. 85.8
ml/m2, p=0.1641; ESVi 33.7 vs. 30.1 ml/m2, p=0.6523;
EF 60 vs. 66 %, p=0.7792; CI 3.7 vs. 3.4 l/min/m2,
p=0.4961.
Conclusions
Left ventricular mass and cardiac index are increased in
patients with acromegaly. The degree of hypertrophy is
not correlated with age or insulin growth factor activity.
The lack of improvement of the left ventricular mass
after 12 months of therapy may be a reflection of
incomplete acromegaly treatment and will require
further studies.
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